Litigation Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
✉ Email this page to a colleague
Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Docket | ⤷ Subscribe | Date Filed | 2020-06-12 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 8,927,592 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Sanofi-Aventis U.S. LLC v. Apotex Corp.
The small molecule drug covered by the patent cited in this case is ⤷ Subscribe .
Details for Sanofi-Aventis U.S. LLC v. Apotex Corp. (D. Del. 2020)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-07-08 | 279 | Report and Recommendations | Defendants for infringement of U.S. Patent No. 8,927,592 (“ʼ592 patent”). Sanofi already sued Defendants… two other patents, U.S. Patent Nos. 10,583,110 (“ʼ110 patent) and 10,716,777 (“ʼ777 patent”). The parties…three patents listed in the Orange Book for cabazitaxel, including the ʼ592 patent and U.S. Patent No. …infringement of the ʼ592 patent and lost. But Sanofi obtained some substitute patent claims during an inter…of the ’592 patent, which claimed methods of using cabazitaxel. (D.I. 255 at 2.) The Patent Trial and | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
